Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ACTRIMS 2022 | What real-world evidence are we lacking in MS?

Namita Tundia, PhD, EMD Serono Inc., Billerica, MA, comments on unanswered questions in the multiple sclerosis (MS) space that real-world data analysis could help to address. With a large variety of disease modifying therapies (DMTs) now approved for use for the treatment of patients with MS, it is important to gather information on the comparative effectiveness of these agents, as well as which agents may be preferable in particular patient subsets or scenarios. Dr Tundia also notes the importance of continuing to analyze the long-term impact of SARS-CoV-2 vaccination in patients with MS. This interview took place at the ACTRIMS Forum 2022 in West Palm Beach, Florida.

Disclosures

Namita Tundia is an employee of EMD Serono.